Get the Stockscreener App
350.78
0.08%
0.29
After Hours:
350.05
-0.73
-0.21%
Penumbra Inc stock is traded at $350.78, with a volume of 3.29M.
It is up +0.08% in the last 24 hours and up +13.85% over the past month.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
See More
Previous Close:
$350.49
Open:
$349.99
24h Volume:
3.29M
Relative Volume:
4.92
Market Cap:
$13.74B
Revenue:
$1.24B
Net Income/Loss:
$42.23M
P/E Ratio:
330.92
EPS:
1.06
Net Cash Flow:
$150.33M
1W Performance:
+8.79%
1M Performance:
+13.85%
6M Performance:
+49.64%
1Y Performance:
+33.73%
1-Day Range:
$349.12
$352.07
1-Week Range:
$290.00
$352.15
52-Week Range:
$221.26
$352.15
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
350.78 | 13.73B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra Shares Soar Pre-MarketWhat Is The Boston Scientific Agreement? - Menafn
Aug Sectors: What analysts say about Penumbra Inc stock2025 Big Picture & Low Drawdown Trading Techniques - baoquankhu1.vn
UnitedHealth Stock Slips Amid Medicare Investigation; Boston Scientific to Acquire Penumbra for $14.5B - Intellectia AI
Halper Sadeh LLC Encourages PEN, CVGW, AVO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
(PEN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
US-based Penumbra preliminary revenue up 22% Q4 2025 - Medical Buyer
Boston Scientific to acquire Penumbra for $14.5 billion By Investing.com - Investing.com Nigeria
RTW Biotech Opp.Boston Scientific to acquire Penumbra - Research Tree
Penumbra (PEN) Receives Neutral Rating with Raised Price Target by Citigroup | PEN Stock News - GuruFocus
PEN: Baird Downgrades Penumbra to 'Neutral', Raises Price Target - GuruFocus
PEN: Truist Securities Downgrades Penumbra to Hold | PEN Stock N - GuruFocus
Penumbra stock hits 52-week high at $321.47 By Investing.com - Investing.com Nigeria
Penumbra Inc. to be Sold to Boston Scientific for $374 per Share - Intellectia AI
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc.PEN - Your Wyoming Link
Penumbra Announces Strong Preliminary Revenue Growth for 2025 - The Globe and Mail
Boston Scientific to acquire Penumbra in $14.5 billion deal - DOTmed
Penumbra (PEN) Climbs to All-Time High on $14.5-Billion Merger - Insider Monkey
PEN Downgraded to Hold by Jefferies; Price Target Raised | PEN S - GuruFocus
Penumbra (PEN) Downgraded to Market Perform by Leerink Partners - GuruFocus
PEN Downgraded to Hold by Needham's Analyst Mike Matson | PEN St - GuruFocus
Needham & Company LLC Reaffirms "Hold" Rating for Penumbra (NYSE:PEN) - MarketBeat
Truist Securities Downgrades Penumbra to Hold From Buy, Adjusts PT to $374 From $370 - marketscreener.com
Analyst Expectations For Penumbra's Future - Benzinga
Citigroup Downgrades Penumbra to Neutral From Buy, Adjusts Price Target to $374 From $350 - marketscreener.com
Boston Scientific: Adding Another Growth Engine With Penumbra (NYSE:BSX) - Seeking Alpha
Boston Scientific announces agreement to acquire Penumbra, Inc. - Med-Tech Insights
This JM Smucker Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last? - Yahoo Finance
Published on: 2026-01-16 16:12:24 - baoquankhu1.vn
Truist Securities downgrades Penumbra stock to Hold following Boston Scientific acquisition - Investing.com Australia
Boston Scientific to acquire Penumbra for $14.5 billion - Investing.com India
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results - BioSpace
RTW Biotech Opportunities Portfolio Company Penumbra To Be Acquired By Boston Scientific - DirectorsTalk Interviews
Penumbra reports preliminary Q4 revenue growth of over 21% By Investing.com - Investing.com Nigeria
Boston Scientific to acquire Penumbra in $14.5 billion deal By Investing.com - Investing.com Nigeria
Boston Scientific Set to Acquire Penumbra in $14.5 Billion Deal to Expand Vascular Therapy Offerings - Hoodline
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead - TechStock²
Penumbra (PEN) Downgraded to Market Perform by William Blair | P - GuruFocus
Boston Scientific to acquire Penumbra for portfolio of vascular treatments - MLex
Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next - TechStock²
[425] Penumbra Inc Business Combination Communication | PEN SEC FilingForm 425 - Stock Titan
Penumbra’s Stock Set to Surge Amid New Price Targets - timothysykes.com
Boston Sci swings for the fences with $14.5B Penumbra buy - BioWorld MedTech
Fenwick Represents Perella Weinberg Partners in Penumbra's $14.5B Acquisition by Boston Scientific - fenwick.com
One of Alameda's largest companies agrees to be acquired for $14.5 billion - The Business Journals
Penumbra’s Bright Future: Analysts Raise Price Targets as MedTech Sector Rebounds - StocksToTrade
Penumbra (PEN) Downgraded by Wells Fargo to Equal-Weight | PEN S - GuruFocus
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Penumbra, Inc. (NYSE: PEN) - PR Newswire
Penumbra (PEN) Shares Surge Nearly 12% - GuruFocus
Penumbra Shares Buoyed by Analyst Upgrades and Market Positivity - timothysykes.com
Penumbra (PEN) Projects 67.1% Gross Margin for Fiscal Year 2025 - GuruFocus
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Penumbra Inc Stock (PEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wilder Thomas | Director |
Jan 02 '26 |
Sale |
310.72 |
186 |
57,794 |
0 |
0.42%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):